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Background: In addition to alterations concerning the expression of oncogenes and onco-suppressors, melanoma
is characterized by the presence of distinctive gangliosides (sialic acid carrying glycosphingolipids). Gangliosides
strongly control cell surface dynamics and signaling; therefore, it could be assumed that these alterations are linked
to modifications of cell behavior acquired by the tumor. On these bases, this work investigated the correlations
between melanoma cell ganglioside metabolism profiles and the biological features of the tumor and the survival
of patients.
Methods: Melanoma cell lines were established from surgical specimens of AJCC stage III and IV melanoma
patients. Sphingolipid analysis was carried out on melanoma cell lines and melanocytes through cell metabolic
labeling employing [3-3H]sphingosine and by FACS. N-glycolyl GM3 was identified employing the 14 F7 antibody.
Gene expression was assayed by Real Time PCR. Cell invasiveness was assayed through a Matrigel invasion assay;
cell proliferation was determined through the soft agar assay, MTT, and [3H] thymidine incorporation. Statistical
analysis was performed using XLSTAT software for melanoma hierarchical clustering based on ganglioside profile,
the Kaplan-Meier method, the log-rank (Mantel-Cox) test, and the Mantel-Haenszel test for survival analysis.
Results: Based on the ganglioside profiles, through a hierarchical clustering, we classified melanoma cells isolated
from patients into three clusters: 1) cluster 1, characterized by high content of GM3, mainly in the form of N-glycolyl
GM3, and GD3; 2) cluster 2, characterized by the appearance of complex gangliosides and by a low content of GM3;
3) cluster 3, which showed an intermediate phenotype between cluster 1 and cluster 3. Moreover, our data demonstrated
that: a) a correlation could be traced between patients’ survival and clusters based on ganglioside profiles, with cluster
1 showing the worst survival; b) the expression of several enzymes (sialidase NEU3, GM2 and GM1 synthases) involved
in ganglioside metabolism was associated with patients’ survival; c) melanoma clusters showed different malignant
features such as growth in soft agar, invasiveness, expression of anti-apoptotic proteins.
Conclusions: Ganglioside profile and metabolism is strictly interconnected with melanoma aggressiveness. Therefore,
the profiling of melanoma gangliosides and enzymes involved in their metabolism could represent a useful prognostic
and diagnostic tool.
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Melanoma is the most lethal form of skin cancer and ac-
counts for at least 48,000 deaths worldwide annually
[1,2]. Clinical outcome of melanoma largely depends on
the tumor stage upon first diagnosis. Currently, melan-
oma staging is based on the guidelines published by the
American Joint Committee on Cancer (AJCC) in 2009
[3] and advises the employment of histopathological and
clinical criteria. Nevertheless, this system is limited in its
ability to provide a precise prognosis: a large number of
patients with similar or identical clinical and histo-
pathological features has different clinical outcome, from
being cured to death [4]. Also, the identification of some
mutations concerning oncogenes, including BRAF,
NRAS, KIT, has been shown to be very useful to predict
the response to therapy, but it is not clear whether the
determination of the mutational status could offer any
prognostic value [5]. Many attempts have been done to
identify molecular markers or gene and protein signa-
tures predicting clinical outcome in melanoma but, so
far, none of them has been sufficiently validated [6-9].
Among the distinctive molecular markers displayed by
melanoma cells, many studies identified specific ganglio-
sides not detectable in normal melanocytes [10]. A pivotal
role played by gangliosides was recognized in the develop-
ment of melanoma and in its biological features [11]. In
particular, GD3 and derivatives [12,13], which are also
present at high levels in proliferating cells [14-16], have
been demonstrated to promote melanoma cell proliferation
and invasion [17]. Moreover, de-N-acetyl GM3 (d-GM3) (a
variant of GM3 with a free amino group at the 5 position
of sialic acid instead of the acetyl group) was found in
melanoma and it was demonstrated that it enhanced
cell migration and invasion [18]. Also, N glycolyl GM3
(Neu5Gc-GM3) (a variant of GM3 that contains N-
glycolylneuraminic acid instead of N-acetylneuraminic acid)
was recognized in melanoma, even its role in this disease is
still obscure [19]. The alteration of the expression/catalytic
activity of glycosyltransferases and enzymes involved in
gangliosides metabolism could be critical factors in deter-
mining the melanoma cell ganglioside composition. In par-
ticular, the activation of GD3 synthase is linked to the
increment of GD3 in melanoma cells [11,20]. Similarly, the
plasma membrane sialidase NEU3 has been shown to be
highly expressed in human melanoma cell lines [21].
Prompted by these data, we sought to investigate the
ganglioside metabolism profile of metastatic melanoma
cell lines established from patients. Our results demon-
strated that: a) melanomas displayed different ganglio-
side patterns and three clusters of tumors could be
identified; b) a correlation could be traced between pa-
tients’ survival and melanoma ganglioside profiles; c) the
expression of several enzymes involved in ganglioside
metabolism was associated with patients’ survival;d) melanoma clusters identified on the basis of ganglio-
side profile exhibited different features determining mel-
anoma malignancy.
Methods
Cell cultures
Melanoma cell lines were established from surgical spec-
imens of AJCC stage III and IV melanoma patients
admitted to Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan [22,23]. Molecular and biological
characterization of the cell lines has been reported pre-
viously [24]. All cell lines were maintained as described
[25]. All patients were informed about the scope and
methods and delivered a written informed consent for
the use of the surgical samples to establish cell lines.
The study was approved by the Ethics Committee of the
University of Milan and was performed according to the
Declaration of Helsinki.
Clones 2/14 and 2/21 were isolated from a single human
metastatic melanoma cell line, as described [26,27].
NHEM-Ad and NHEM-Neo were purchased by Lonza
(Basel, Switzerland) and PromoCell (Heidelberg, Germany),
and maintained in mMGM-4 medium (Lonza).
Sphingolipid analysis
Sphingolipid analysis was carried out through cell me-
tabolic labeling with [3-3H]sphingosine (PerkinElmer,
Waltham, MA, USA) [28]. In order to assay the hypoth-
esis that Neu5Gc-glicans could be incorporated from the
culture medium and then employed for the synthesis of
GM3, before [3-3H]sphingosine labeling, melanoma L6
cells were pre-incubated in the reduced-serum medium
OptiMEM (Life Technology, Carlsbad, CA, USA) for
5 days.
Ganglioside and neutral sphingolipid extracts were an-
alyzed by HPTLC carried out with the solvent systems
chloroform/methanol/0.2% CaCl2 55:45:6 (v/v) and
chloroform/methanol/water 110:40:6 (v/v), respectively.
To separate Neu5Gc-GM3 from Neu5Ac-GM3, HPTLC
was carried out using the solvent system chloroform/
methanol/0.2% CaCl2/5 N NH3 50:42:6:4 (v/v). The
sphingolipid pattern was determined and quantified by
radiochromatoscanning (Betaimager 2000, Biospace, Paris,
France) [28,29].
Endogenous sphingolipid analysis performed to stan-
dardize metabolic labeling was performed as previously
described [30].
Ganglioside standards were kindly given by Prof.
Sonnino, University of Milan.
Immunostaining of HPTLC
After the chromatographic separation of gangliosides,
the plates were soaked in acetone plus 0.1% polyisobu-
tylmethacrylate. After drying and blocking with PBS-4%
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Neu5Gc-GM3 murine 14 F7 antibody [31,32], overnight,
and, then, with a horseradish peroxidase-conjugated
anti-mouse IgG antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The reaction was stained with
the SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific, Dallas, MA, USA).
Immunohistochemical analysis
Cytospin preparations of melanoma cell lines were fixed
with formalin for 10 min at room temperature and then
incubated with 14 F7 mAb, as described [19]. The slides
were then incubated with goat anti-mouse biotinylated
secondary antibody, followed by streptavidin/HPR (Dako,
Glostrup, Denmark), for 30 min at each step. The enzyme
activity was detected with a commercial solution of 3, 3′-
Diaminobenzidine (Sigma-Aldrich, St Louis, MO, USA).
Cells were counterstained with Mayer’s Hematoxylin
(Bio-Optica, Milan, Italy). Slides subjected to the same
treatments, but without incubation with primary mAb,
were used as negative controls. Images were acquired
at × 20 with an Axiovert 100 microscope (Zeiss, Carl
Zeiss, Thornwood, NY) equipped with a digital camera
(AxioCam MrC5, Zeiss).
Phenotypic profile of melanoma cell lines
Cell surface expression of GM3, GD2 and GD3 was
determined in representative melanoma cell lines be-
longing to different clusters, by staining with the follow-
ing mAbs: anti GM3 (Neu5Ac-GM3) M2590 (Cosmo
Bio Co, LTD, Tokyo, Japan), anti-human disialoganglio-
side GD2 (BD Pharmingen, San Diego, CA, USA), anti-
ganglioside GD3 (R24) (Abcam Inc., Cambridge, UK),
followed by a FITC-conjugated F(ab’)2 fragment goat anti-
mouse Ab (Jackson ImmunoResearch, West Grove, PA) as
described [33]. Samples were acquired by a fluorescence-
activated cell sorting (FACS)-Calibur cytofluorimeter (BD
Biosciences) and analyzed by the FlowJo software (Tree
Star, Ashland, OR, USA). Results were expressed as per-
centage of positive cells and as mean fluorescence intensity
after subtraction of mean fluorescence intensity in cells
stained with secondary antibody only.
In order to compare the phenotype of different tumors,
all main FACScan operative settings were kept constant
throughout the whole study.
PCR and Real-time RT-PCR
CMAH expression was assayed in cDNA isolated from
melanocytes and melanoma cells through RT-PCR. The
genomic region corresponding to the 92-bp deletion in
the human CMAH gene was amplified by PCR using
genomic DNA extracted from melanoma cells and from
murine C2C12 cells, as positive control. Real Time PCRwas performed as previously reported [34]. Primer se-
quences are reported in Table 1.
Invasiveness assay
Melanoma cell invasiveness was assayed through a
Matrigel assay, as previously reported [35].
Proliferation assays
Soft agar, thymidine incorporation, and MTT assays
were performed as previously reported [34].
Sialidase activity toward endogenous cell gangliosides
To test the ability of melanoma plasma membrane si-
alidase to act on endogenous cell gangliosides, melan-
oma cell particulate fractions, obtained as previously
described [36], were incubated with [3-3H]sphingosine
labeled cell gangliosides at pH 3.8, overnight, at 37°C.
Then, gangliosides were fractionated by HPTLC and vi-
sualized by radiochromatoscanning.
Statistical analysis
Hierarchical clustering was done using XLSTAT soft-
ware. Survival analysis was carried out by the Kaplan-
Meier method; survival curves were compared by the
log-rank (Mantel-Cox) test; hazard ratios were com-
puted by the Mantel-Haenszel test. Ganglioside compos-
ition, Real Time PCR data, [3H]thymidine incorporation
were compared using Student t-test and 1-way ANOVA.
Results
Melanoma cells can be clustered on the basis of their
ganglioside profile
Sphingolipid pattern was determined in 23 short-term
cell lines established from 5 primary VPG (vertical
growth phase) melanomas and from 18 lymph nodes
metastases as well as in adult (NHEM-Ad) and neonatal
(NHEM-Neo) melanocytes. To this end, [3-3H]sphingo-
sine was administrated to the cells leading to an exten-
sive labeling of all sphingolipids [37]. The treatment
was performed in order to reach a metabolic steady
state that corresponded to endogenous non-radiolabelled
cell sphingolipid pattern. NHEM-Ad and NHEM-Neo
melanocytes ganglioside profile was mainly composed of
GM3 and GD3 (in traces in NHEM-Ad cells and more
abundant in NHEM-Neo cells) with traces of sialyl-
paragloboside (SPG) (Additional file 1).
The distinct ganglioside profiles of melanoma cells
allowed us to classify them into three main groups
(Figure 1A). The ganglioside HPTLC pattern of NHEM-
Ad and NHEM-Neo melanocytes and of representative
cell lines of each cluster is shown in Figure 1B. Melanoma
cells belonging to cluster 1 showed a strong similarity with
neonatal melanocytes, with GM3 as the main ganglioside
and an increased amount of GD3 (Additional file 1,
Table 1 Primers used for gene expression
Gene Forward primer Reverse primer
GD3 synthase (ST8SIAI) 5′-CAGCATAATTCGGCAAAGGT-3′ 5′-ATTGGCACCAACATCTGACA-3′
NEU1 5′-CCTGGATATTGGCACTGAA-3′ 5′-CATCGCTGAGGAGACAGAAG-3′
NEU2 5′-AGAAGGATGAGCACGCAGA-3′ 5′-GGATGGCAATGAAGAAGAGG-3′
NEU3 5′-GGCTTGTTTGGGTGTTTGTT-3′ 5′-CATCGCTGAGGAGACAGAAG-3′
NEU4 5′-ACCGCCGAGAGTGTTTTGG-3′ 5′-CGTGGTCATCGCTGTAGAAGG-3′
GM3 synthase (ST3GAL5) 5′-CCCTGAACCAGTTCGATGTT-3′ 5′-CATTGCTTGAAGCCAGTTGA-3′
GM1 synthase (B3GALT4) 5′-CGCCTTCCAGGACTCCTACC-3′ 5′-CCGTCTTGAGGACGTATCGG-3′
GM2 synthase (B4GALNT1) 5′-TCTCACTGGAGAGGGTCAGG-3′ 5′-CGGACTGTGTCTGCTGTGTT-3′
GD1a synthase (ST6GALNAC4) 5′-TCTACCACCCAGCCTTCATC-3′ 5′-TAGTGGTGCCAGTTCCCTTT-3′
ST3GalVI 5′-TTGCCCTATGGGATGAGAAC-3′ 5′-CCTCCATTACCAACCACCAC-3′
ST3GalNac6 5′-CGCCGGAGAGAAATGAGTA-3′ 5′-CCACTTCTTGAGGTTGACAGG-3′
SP1 5′-GGCTACCCCTACCTCAAAGG-3′ 5′-CACAACATACTGCCCACCAG-3′
CMAH 5′-GAATTTATTGTCCCTTTGC-3′ 5′-TATGATGCCCTTGCTGTC-3′
CMAH deletion 5′-AGCTTTCCGGAGGGTTGATA-3′ 5′-TGTCAGATGCACAAGCACAA-3′
ACTB (β actin) 5′-CGACAGGATGCAGAAGGAG-3′ 5′-ACATCTGCTGGAAGGTGGA-3′
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to clusters 2 and 3 were significantly different from that of
melanocytes, revealing the appearance of novel species
such as GM2, GD1a, GD2, GT1b in cluster 2, and GM2,
GD1a, GD2 in cluster 3, in addition to GM3 and GD3
(Additional file 1, Figure 1B). No significant differences
were found considering primary lesions versus metastasesFigure 1 Association of melanoma cell ganglioside profile with patients
the basis of ganglioside profiles. Dotted line represents the level of significant
sphingolipids of three representative melanoma cell lines (L6, L34, L4) belong
melanocytes. (D) Kaplan-Meier survival analysis of patients according to the thor the clinical stage of the disease at the time when
tumors were surgically removed and cell lines established
(AJCC stage III versus stage IV) (Additional file 1).
Despite these huge differences regarding the ganglioside
profiles of the three clusters, neutral sphingolipid pattern
was quite similar also to adult and neonatal melanocytes
pattern, except for a 30-40% decrease of ceramide amount’ survival. (A) Hierarchical clustering analysis of melanoma cell lines on
dissimilarity. (B) HPTLC separation of gangliosides and (C) of neutral
ing to clusters 1, 2, and 3, in comparison to adult and neonatal
ree clusters identified. Survival was evaluated as time from first diagnosis.
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fied in cluster 2 (P < 0.05) (Figure 1C).
Kaplan-Meier survival analysis and log-rank test demon-
strated that patients whose tumors fell in cluster 1 had a
significantly worse overall survival, measured from the
time of the first diagnosis, in comparison to patients
whose tumors were classified in cluster 3 and, above all, in
cluster 2 (P < 0.05) (Figure 1D). Patients belonging to clus-
ter 1 had a hazard ratio of 4.23 in comparison to patients
belonging to cluster 2 (P < 0.05), and a hazard ratio of 2.91
as compared with patients belonging to cluster 3 (P < 0.05).
The ganglioside phenotypic profile of representative cell
lines for each cluster is reported in Figure 2. A low hetero-
geneity was observed concerning the content of GD3 and
GD2 in some cell lines.
A high amount of N-glycolyl GM3 characterizes melanoma
cluster 1 cells
We recorded a singular trend showing a marked decrease
of the average GM3 per cent content from melanoma
cluster 1 cells to cluster 3 (−58.3%; cluster 3 versus cluster
1, P < 0.001), and to clusters 2 (−76.5%; cluster 2 versus
cluster 1, P < 0.001) (Figure 3A). This trend was associated
with the decrease of GM3 synthase expression in clusters
2 and 3, in comparison to cluster 1 (−85.7%, cluster 2 ver-
sus cluster 1; −82.1% cluster 3 versus cluster 1; P < 0.001)
(Figure 3B). To confirm the key role played by GM3 in
metastatic melanoma behavior, we analyzed the ganglio-
side composition of two melanoma clones (2/14 and 2/21)
isolated from a single melanoma cell line [26]. These two
clones had markedly different molecular and biological
features [26,27], including adhesion molecule phenotype,
degree of differentiation, recognition by antigen-specific T
cells, presence of mutated NRAS (clone 2/14) or mutated
BRAF (clone 2/21), growth in immunodeficient mice (en-
hanced in clone 2/14) [26,27]. Significantly, the ganglioside
profile of clone 2/14 consisted only of GM3 (Figure 4A).
We assessed that a high amount of GM3 was present in
clone 2/14, as well as in melanoma cell lines, as Neu5Gc-
GM3. Neu5Gc-GM3 was detected also in melanocytes.
d-GM3 was not present (Figure 4A). The increase of GM3
in melanoma cluster 1 cells reflected an increased content
of Neu5Gc-GM3 (90% of total cellular GM3) in compari-
son to other clusters (Figure 4B). The identification of
Neu5Gc-GM3 was validated by the employment of the
Neu5Gc-GM3-specific antibody 14 F7 [19] in HPTLC
immunostaining (Figure 4C) and in immunohistochemical
analysis, which confirmed its enhanced amount in cluster 1
melanoma cells (Figure 4D). Because it was reported that
N-glycolylneuraminic acid synthesis could not occur in
human cells due to a 92 bp sequence deletion in the
CMAH gene that blocks the synthesis of a functional form
of CMP-NeuAc hydroxylase (CMAH), the enzyme respon-
sible for the conversion of CMP-N-acetylneuraminic acidinto CMP-N-glycolylneuraminic acid [38,39], firstly we ex-
plored if this genetic alteration was reverted in melanoma
cells. We recorded CMAH expression as mRNA in all
melanoma cell lines, in contrast to melanocytes where it
was null (Figure 5A). Nevertheless, we demonstrated that
the CMAH gene maintained the 92 bp sequence deletion
typical of human cells [40], also in melanoma cells
(Figure 5B); therefore, on the basis of previous evidences
[41], this gene cannot be translated into an enzymatically
active protein. Many reports demonstrated that some can-
cer cells become able to incorporate dietary CMP-N-
acetylneuraminic acid at a faster rate from biological fluids
and therefore, they incorporate it into gangliosides. Effect-
ively, we demonstrated that cultivating melanoma cells in a
serum-reduced medium for 5 days, the content of
Neu5Gc-GM3 was reduced by 25% (P < 0.01) (Figure 5C).
Therefore, we concluded that melanoma cells do not gain
the capability to synthetize CMP-N-acetylneuraminic acid
but they can acquire it from external molecules.Correlation between glycosyltransferases expression and
patients’ survival
We confirmed an overall higher expression of GD3
synthase (11.5-1.5-fold) and plasma membrane sialidase
NEU3 (7–1.5-fold) in all melanoma cells than melanocytes
(Figure 6A,B) [11,21]. The increase of the expression of
these two enzymes was reasonably induced by the
enhanced expression of the transcriptional factors Sp1
(average increase: 100%, melanoma cells versus adult mela-
nocytes; P < 0.001) (Figure 6C), as it was reported that both
NEU3 [42] and GD3 synthase gene promoters [43] are
regulated by them. NEU3 was the unique sialidase to be
over-expressed by melanoma cells; lysosomal sialidase
NEU1 expression varied inconsistently among melanoma
cell lines and melanocytes; cytosolic sialidase NEU2 was
not expressed in both melanocytes and melanoma cells;
sialidase NEU4 appeared to be down-regulated in all
melanoma cells except L1, L34, L39, L40, in comparison to
melanocytes. As melanoma cells expressed high levels of
GM3, the increase of NEU3 expression appeared a paradox.
Therefore, we tried to assess if endogenous GM3 could be
accessible to NEU3 activity in melanoma cells. To this end,
after metabolic labelling with [3-3H]sphingosine, gang-
liosides were extracted from a representative melanoma cell
line belonging to cluster 1 (L6) and incubated with mem-
branes obtained by the same cell line, in order to perform
an exhaustive treatment. We demonstrated that NEU3 was
able to hydrolyze and convert into lactosylceramide only
41% of plasma membrane GM3: the aliquot of Neu5Gc-
GM3 was particularly resistant to sialidase action (−25-
30%), while N acetyl GM3 (Neu5Ac-GM3) was entirely
hydrolyzed. Also, GD3 and SPG decreased by 22%
and 34%, respectively, after incubation (pre-incubation
Figure 2 Ganglioside phenotypic profile of melanoma cell lines. Cell surface staining of GM3, GD2, and GD3 by mAbs: anti Neu5Ac-GM3 (M2590);
anti-GD2, anti-GD3 (R24), determined in representative melanoma cell lines belonging to different clusters (L40 and L23 for cluster 1; L1 and L34 for
cluster 2; L2 and L16 for cluster 3).
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(Figure 6D,E).
We recorded in some melanoma cell lines grouped, par-
ticularly, in clusters 2 and 3, the expression of GM1 andGM2 synthases that were not expressed by melanocytes
(Figure 7A). The expression of GM1 and GM2 synthases
was related to the appearance of GM1 and GM2 among
the gangliosides of these cells (Additional file 1). Kaplan-
Figure 3 Correlation between GM3 amount and melanoma cell malignancy. (A) GM3 content and (B) Real Time PCR analysis of the mRNA
expression of GM3 synthase in melanoma cells and in melanocytes. Values are the mean ± S.D. of four independent experiments.
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patients whose tumors showed a relative mRNA expression
of GM1 synthase, normalized on β actin, higher than 1 had
a significantly better overall survival, measured from the
time of the first diagnosis, in comparison to patients whoseFigure 4 Correlation between Neu5Gc-GM3 and melanoma cell malig
and 2/21) isolated from a single patient. (B) HPTLC separation of Neu5Ac-G
melanoma cell lines representative of cluster 1 (L6), cluster 2 (L34), cluster 3
HPTLC (NHEM-Ad, NHEM-Neo, L6 representative of cluster 1, L34 representativ
analysis of cytospin preparations of L6 representative of cluster 1 and L34
magnification, x20 (Axiovert 100). Similar results were obtained for other mtumors showed a less relative mRNA expression of this
enzyme (P < 0.01) (Figure 7B). Patients carrying tumors
endowed with GM1 synthase low expression had a hazard
ratio of 4.499 in comparison to other patients (P < 0.01).
Similarly, patients whose tumors showed a relative mRNAnancy. (A) HPTLC separation of gangliosides of two cell clones (2/14
M3 and Neu5Gc-GM3 in NHEM-Ad, NHEM-Neo, clone 2/14, and in
(L4). (C) 14 F7 antibody immunostaining of gangliosides separated by
e of cluster 2, L4 representative of cluster 3. (D) Immunohistochemical
representative of cluster 2, stained with 14 F7 antibody. Original
elanoma cell lines according to the clustering.
Figure 5 CMAH in melanoma cells. (A) RT-PCR analysis of CMAH
expression in L6 (cluster 1), L34 (cluster 2), L4 (cluster 3). (B) RT-PCR
analysis of deletion at 5′ of CMAH gene in L6 (cluster 1), L34 (cluster 2),
L4 (cluster 3). Similar results were obtained for other melanoma cell lines
according to the clustering. (C) HPTLC separation of gangliosides of L6
cells after pre-incubation in medium containing 10% FBS or in serum-
reduced medium OptiMEM. Three replicate experiments were performed.
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higher than 1.5 had a significantly better overall survival,
measured from the time of the first diagnosis, in compari-
son to other patients (P < 0.05) (Figure 7C). Low or null
expression of GM2 synthase entailed for patients a hazard
ratio of 3.5 in comparison to high expression (P < 0.01).
Overall, melanomas that showed high expression of both
GM1 and GM2 synthases were associated with an overall
survival longer than 5 years, while the lack of both these
glycosyltransferases increased the hazard ratio to 6.325
(P < 0.01) (Figure 7D). All melanoma cluster 2 cells and the
majority of melanoma cluster 3 cells expressed both GM1
and GM2 synthases (Figure 7A).
We also analyzed the expression of other glycosyl-
transferases involved in ganglioside metabolism such
as GD1a synthase, ST3GalVI, ST6GalNAc6 (data not
shown) but we did not identify any correlation with
patients’ survival.Correlation between melanoma cell ganglioside profile
and growth/survival and invasive potential
The anchorage-independent growth potential of melan-
oma cells was assessed through a soft agar assay. Melan-
oma 1 cells were able to form more and larger colonies in
soft agar than were melanoma cluster 2 cells (4.1-fold; P <
0.01), and than were melanoma cluster 3 cells (2-fold; P <
0.01) (average colony forming efficiency: cluster 1: 53%,
cluster 2: 13%; cluster 3: 27%) (Figure 8A). This different
potential of growth in soft agar did not reflect a similar in-
hibition of proliferation capability. In fact, [3H] thymidine
incorporation was similar between melanoma cluster 1
and 2 cells and even higher in cluster 3 (Figure 8B); MTT
assay did not reveal any difference among the three clus-
ters (Figure 8C). Therefore, we could not conclude that
the ganglioside profile of the three clusters was determin-
ant for the proliferation rate but only for the tumorigen-
icity measured as capability to grow in soft agar.
In the Matrigel invasion assay, cluster 1 cells revealed to
be more invasive than cluster 2 and 3 cells (+37%; P < 0.01)
(Figure 8D).
The resistance to apoptosis evidenced by the expression
of BCL-2 and BCL-XL was clearly different between the
three clusters: melanoma cells grouped in cluster 1
showed a higher expression of BCL-2 than melanocytes
and also than melanoma cells grouped in clusters 2 and 3
(+150% versus adult melanocytes, P < 0.001; +150% versus
cluster 2, P < 0.001; +900% versus cluster 3, P < 0.001) and
BCL-XL (+38% versus adult melanocytes, P < 0.01; +57%
versus cluster 2, P < 0.001; +38% versus cluster 3, P < 0.01)
(Figure 8E).
Discussion
The expression of atypical gangliosides deeply marks
melanoma [20]. This study demonstrated that melano-
mas could be classified based on their ganglioside profile
and that there is a significant correlation between the
ganglioside pattern displayed by melanomas and their
biological and clinical behavior. Ganglioside biosynthesis
occurs via two major pathways designed “a” (GM2,
GM1, GD1a, and GT1a) and “b” (GD3, GD2, GD1b, and
GT1b) with a common precursor (GM3) (Figure 9). In-
triguingly, melanoma cells that we grouped in cluster 1,
retrieved and exacerbated ganglioside biosynthetic path-
ways typical of neonatal melanocytes, characterized by a
high content of GD3 (“b” series) and GM3. GD3 could be
considered a typical fetal ganglioside [44]. In melanoma
cells, GD3 was demonstrated to enhance the adhesion and
proliferation properties by recruiting integrins and signal
molecules to lipid rafts [20,45]. Furthermore, the 9-O
acetylation of GD3 (to form 9-OAc-GD3) was described
in melanoma [46]: this chemical modification suppresses
the pro-apoptotic function of GD3 [47]. Moreover, 9-OAc-
GD3 is an important regulatory molecule being involved in
Figure 6 Up-regulation of GD3 synthase and NEU3 in melanoma cells. (A) Real Time PCR analysis of the mRNA expression of GD3 synthase
and (B) of NEU3 sialidase in melanoma cell lines and in melanocytes. Dotted line represents GD3 synthase and NEU3 expression level in adult
melanocytes. Values are the mean ± S.D. of four independent experiments. (C) Average mRNA expression of Sp1, assessed by Real Time PCR, in
melanoma cell lines and in melanocytes. Values are the mean ± S.D. of four independent experiments. (D) HPTLC separation and (E) percent
quantification of melanoma cell (L6) gangliosides before and after incubation with melanoma cell membranes.
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ation [47]. Regarding GM3, it should be noted that, in
cluster 1, it was principally in the form of Neu5Gc-GM3
instead of Neu5Ac-GM3. N-glycolylneuraminic acid syn-
thesis has been considered to be absent in normal human
tissues due to a partial deletion of the gene coding for
CMAH [38,39]. We demonstrated that melanoma cells
characteristically expressed CMAH cDNA. Nevertheless,
also in melanoma cells, CMAH gene carried the 92 bp
deletion [40]. Thus, it cannot be hypothesized that thesynthesis of N-glycolylneuraminic acid could be rescued
in melanoma cells. Otherwise, we determined that
Neu5Gc-GM3 amount in melanoma cells depended on
the external medium. Therefore, it can be supposed that
melanoma cells, in particular those grouped into cluster 1,
could incorporated N-glycolylneuraminic acid in a faster
way, as described for other tumors [38]. It has been
previously showed a correlation between CMAH mRNA
expression and an increased ability of human stem cells to
bind and possibly ingest exogenous N-glycolylneuraminic
Figure 7 Altered expression of GM1 and GM2 synthases in melanoma cells. Correlation with patients’ survival. (A) GM1 and GM2
synthases expression assessed by Real Time PCR in melanoma cells separated in three clusters. Grey color denotes the expression of the enzyme,
white color the absence. Values are the mean ± S.D. of four independent experiments. (B) Kaplan-Meier survival analysis of patients according to
GM1 synthase expression, (C) according to GM2 synthase expression, and (D) according to both GM1 and GM2 synthases expression. Survival was
evaluated as time from first diagnosis.
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http://www.biomedcentral.com/1471-2407/14/560acid [48]. Therefore, it could be speculated that the
appearance of CMAH protein, even though enzymati-
cally inactive, could play a role in the incorporation of
external N-glycolylneuraminic acid. The incorporation of
N-glycolylneuraminic acid in vivo could possibly occur
from biological fluids. In fact, the presence of Neu5Gc-
GM3 in melanoma surgical specimens was previously
largely documented [19,32,49]. Moreover, melanoma
cluster 1 cells were characterized by the highest levels
of expression of GM3 synthase: therefore, also N-
glycolylneuraminic acid could be recruited faster into
GM3, in these conditions. The increase of Neu5Gc-
GM3 was demonstrated to enhance the aggressive
behavior of cancer. Mouse B16 melanoma cells loaded
with Neu5Gc-GM3 showed more lung metastases and
increased tumor burden in subcutaneous implants [50].
Moreover, on the contrary of Neu5Ac-GM3, Neu5Gc-
GM3 did not inhibit EGF-induced EGFR phosphorylation
in A431 cells [51] and down-modulated CD4 molecule
in T lymphocytes [52] and dendritic cell differentiation
[53]. To further confirm the involvement of GM3 and
Neu5Gc-GM3 in melanoma aggressiveness, we demon-
strated that a clone isolated from a single melanoma cellline and endowed with higher adhesive and invasive
potential, showed a ganglioside pattern composed only
by GM3, mainly in the form of Neu5Gc-GM3. Neu5Gc-
GM3 was not efficiently hydrolyzed by plasma mem-
brane sialidase and this explains why melanoma cells
could accumulate it despite the high expression of
NEU3. In our melanoma cells, we could not identify d-
GM3 in contrast to Liu et al. who quantified d-GM3 as the
major GM3 species present in melanoma [18]. Summing
up, melanoma cluster 1 cells showed a ganglioside profile
that appeared to confer the highest malignant properties in
terms of growth in soft agar medium, in vitro invasiveness,
and expression of anti-apoptotic proteins. Also, the increase
of BCL-2 and BCL-XL could be the direct consequence of
an altered control of growth factor receptors such as EGFR,
due to the increase of both GD3 [54] and Neu5Gc-GM3
[51] on the plasma membrane.
Melanoma cluster 2 cells completely revolutionized
the usual pathways of ganglioside biosynthesis present in
melanocytes and acquired the expression of GM1 and
GM2 synthases. Their ganglioside pattern was enriched
by the presence of complex gangliosides such as GD1a
and GT1b, belonging to the “a” pathway, which were not
Figure 8 Growth, invasiveness, and survival potential of melanoma clusters. (A) Images of colonies formed by representative melanoma
cells grouped in cluster 1 (L6), 2 (L1), and 3 (L4) in the soft-agar assay after 3 weeks of incubation at 37°C. Original magnification x4 (Olympus
Ix50). Three replicate experiments were performed. Similar results were obtained for other melanoma cell lines according to the clustering. (B)
Average value of proliferation of melanoma cells grouped in cluster 1, 2, and 3 assessed using [3H] thymidine incorporation and (C) MTT assay.
NS: non significant. Four replicate experiments were performed. (D) Average invasiveness potential assessed by Matrigel invasion assay of melanoma
cells grouped in cluster 1, 2, and 3. Three replicate experiments were performed. (E) Average mRNA expression of BCL-2 and BCL-XL in melanoma cell
lines classified in clusters 1, 2, and 3 and in adult melanocytes. Dotted line represents BCL-2 and BCL-XL expression level in adult melanocytes. Values
are the mean ± S.D. of four independent experiments.
Figure 9 Schematic picture of ganglioside synthesis pathways.
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http://www.biomedcentral.com/1471-2407/14/560revealed in melanocytes, and to the “b” pathway. It was
previously demonstrated that the transfection of GM1
synthase cDNA into the melanoma cell line SK-MEL-37
gave rise to the neo-expression of GD1b, GT1b, and
GM1 and, in parallel, reduced cell growth and invasion
[55]. In melanoma cluster 2 cells, the expression of GM3
synthase was similar to adult melanocytes and, also, the
content of GM3 and Neu5Gc-GM3 was significantly less
than melanoma cluster 1 cells. Melanomas classified in
cluster 3 represented a middle situation between that
displayed by melanoma cluster 1 and melanoma cluster
2 with low Neu5Gc-GM3 levels and GM3 synthase ex-
pression and the presence of GD1a. Accordingly to these
different ganglioside profiles, also the in vitro malignant
behavior showed by these two clusters was clearly weak-
ened. Thus, it appears realistic that the synthesis of dif-
ferent gangliosides, altering the recruiting and activation
of signal molecules, could reflect on the biological prop-
erties of melanoma. Significantly, also the clinical behav-
ior was very different: we traced a correlation between
melanoma clusters and patients’ survival. In particular,
the synthesis of GM3/GD3 and of “a” complex gangliosides
appeared to have a worst and good prognostic value, re-
spectively. Intriguingly, melanomas that retrieved a ganglio-
side metabolism typical of immature melanocytes (cluster
1), showed the worst outcome (median survival lower than
10 months). It could be supposed that this phenotype
corresponds to a higher motile behavior: in fact, neural
crest-derived melanoblasts are highly migratory cells [56].
Instead, complex gangliosides, such as GD1a, usually de-
note more differentiated cells [57]. In the past, pioneering
studies have indicated that the GM3: GD3 ratio could be
followed for the prognosis and therapeutic management of
melanoma [58]. Our results demonstrated that the overall
cell ganglioside profile and metabolism could be more
important than the presence of a single ganglioside type like
GD3 or N-glycolyl GM3 for cell biologic features and,
therefore, for prognosis.
Sialidase NEU3 and GD3 synthase genes were signifi-
cantly up-regulated in melanomas in comparison to
melanocytes, possibly as a direct consequence of the
increase expression of the transcriptional factor Sp1, but
we cannot record any significant correlation with
patients’ survival. Sialidase NEU3 could be involved in
melanoma malignancy decreasing the levels of Neu5Ac-
GM3. It should also be noted that previous papers dem-
onstrated that NEU3 is able to modulate cell signaling
also inducing minimal changes in ganglioside profile
[21,59] and that NEU3 up-regulation could be counter-
balanced by other modifications concerning the expres-
sion of enzymes involved in ganglioside metabolism,
including GM3 synthase, inducing not expected effects
on gangliosides [60]. Therefore, the impact of NEU3 up-
regulation in melanoma could be complex and shouldbe further investigated in forthcoming works. In sum-
mary, the following factors appeared to be determinant
for melanoma behavior and could have a significant
prognostic value: a) the levels of GM3 and GD3; b) the
levels of gangliosides GM1, GD1a, GT1b; c) GM3, GM1,
and GM2 synthases expression. Therefore, the determin-
ation of ganglioside pattern could significantly improve
the prediction of clinical outcome and possibly help the
design of the most appropriate therapeutic strategy.
Conclusions
In addition to be classified on the basis of characteristic
genetic mutations, different types of melanomas could
also be distinguished on the basis of ganglioside profile.
This analysis that could be performed in histochemistry
also on surgical specimens, could indicate the aggres-
siveness of the tumor and, therefore, improve the predic-
tion of the clinical outcome.
Additional file
Additional file 1: Clinical data and ganglioside composition of
melanoma cell lines and melanocytes. Origin of the cell line: VPG
primary tumors (black); metastasis (grey).
Abbreviations
AJCC: American Joint Committee on Cancer; d-GM3: de-N-acetyl GM3;
Neu5Gc-GM3: N glycolyl GM3; Neu5Ac-GM3: N acetyl GM3; VPG: Vertical
growth phase; NHEM-Ad: Adult melanocytes; NHEM-Neo: Neonatal
melanocytes; SPG: Sialyl-paragloboside; CMAH: CMP-NeuAc hydroxylase; GM3
synthase: ST3 beta-galactoside-alpha-2,3-sialyltransferase-5; GD3 synthase: ST8
alpha-N-acetyl-neuraminide-alpha-2-8-sialyltransferase; GM2 synthase: Beta-
1,4-N-acetyl-galactosaminyltransferase-1; GM1 synthase: UDP-gal,betaGlcNAc-
beta-1,3-galactosyltransferase; GD1a synthase: ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase.
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
CT: conception and design, acquisition of data, analysis and interpretation of
data, writing of the manuscript; IS: acquisition of data, analysis and
interpretation of data; FT: acquisition of data; PB: acquisition of data; LA:
revision of the manuscript; RM: conception and design; AA: conception and
design; ALR: acquisition of data; GT: revision of the manuscript; BV:
conception and design, study supervision, revision of the manuscript.
All authors read and approved the final manuscript.
Acknowledgments
Grant supports: Fondazione Cariplo (2010–0700), AIRC (IG-13131) to BV,
and AIRC (IG-6036) to RM.
Author details
1Department of Medical Biotechnology and Translational Medicine,
University of Milan, Segrate, Milan, Italy. 2Human Tumors Immunobiology
Unit, Department of Experimental Oncology and Molecular Medicine,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 3Laboratory of
Stem Cells for Tissue Engineering, IRCCS Policlinico San Donato, San Donato
Milanese, Milan, Italy. 4Department of Biomedical Sciences for Health,
University of Milan, Segrate, Milan, Italy. 5Immunobiology Department, Center
of Molecular Immunology, Havana, Cuba.
Tringali et al. BMC Cancer 2014, 14:560 Page 13 of 14
http://www.biomedcentral.com/1471-2407/14/560Received: 18 March 2014 Accepted: 28 July 2014
Published: 1 August 2014
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74–108.
2. Miller AJ, Mihm MC Jr: Melanoma. N Engl J Med 2006, 355:51–65.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR,
Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT,
Gimotty PA, Kirkwood JM, McMasters KM, Mihm M, Morton DL, Ross MI,
Sober AJ, Sondak VK: Final version of AJCC melanoma staging and
classification. J Clin Oncol 2009, 2009(27):6199–6206.
4. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 2005,
365:687–701.
5. Haass NK, Smalley KS: Melanoma biomarkers: current status and utility in
diagnosis, prognosis, and response to therapy. Mol Diagn Ther 2009,
13:283–296.
6. Gould Rothberg BE, Rimm DL: Biomarkers: the useful and the not so
useful–an assessment of molecular prognostic markers for cutaneous
melanoma. J Invest Dermatol 2010, 130:1971–1987.
7. Baruthio F, Quadroni M, Ruegg C, Mariotti A: Proteomic analysis of
membrane rafts of melanoma cells identifies protein patterns characteristic
of the tumor progression stage. Proteomics 2008, 8:4733–4747.
8. Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J:
A nine-gene signature predicting clinical outcome in cutaneous melanoma.
J Cancer Res Clin Oncol 2013, 139:249–258.
9. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ: Review and
cross-validation of gene expression signatures and melanoma prognosis.
J Invest Dermatol 2012, 132:274–283.
10. Hakomori S: Tumor-associated carbohydrate antigens defining tumor
malignancy: basis for development of anti-cancer vaccines. Adv Exp Med
Biol 2001, 491:369–402.
11. Ruan S, Raj BK, Lloyd KO: Relationship of glycosyltransferases and mRNA
levels to ganglioside expression in neuroblastoma and melanoma cells.
J Neurochem 1999, 72:514–521.
12. Portoukalian J, Zwingelstein G, Dore JF: Lipid composition of human
malignant melanoma tumors at various levels of malignant growth. Eur J
Biochem 1979, 94:19–23.
13. Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM: Gangliosides of
normal and neoplastic human melanocytes. Biochem Biophys Res
Commun 1984, 120:500–504.
14. Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS: Developmental changes in
ganglioside composition and synthesis in embryonic rat brain.
J Neurochem 1988, 50:1825–1829.
15. Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, Cordon-Cardo C,
Buhrer C, Old LJ, Houghton AN: Stimulation of T lymphocyte proliferation
by monoclonal antibodies against GD3 ganglioside. J Immunol 1987,
139:1763–1771.
16. Yamashiro S, Okada M, Haraguchi M, Furukawa K, Lloyd KO, Shiku H,
Furukawa K: Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene
in human cancer cell lines: high level expression in melanomas and
up-regulation in activated T lymphocytes. Glycoconj J 1995, 12:894–900.
17. Furukawa K, Hamamura K, Nakashima H, Furukawa K: Molecules in the
signaling pathway activated by gangliosides can be targets of
therapeutics for malignant melanomas. Proteomics 2008, 8:3312–3316.
18. Liu JW, Sun P, Yan Q, Paller AS, Gerami P, Ho N, Vashi N, Le Poole IC, Wang
XQ: De-N-acetyl GM3 promotes melanoma cell migration and invasion
through urokinase plasminogen activator receptor signaling-dependent
MMP-2 activation. Cancer Res 2009, 69:8662–8669.
19. Blanco R, Rengifo E, Rengifo CE, Cedeno M, Frometa M, Carr A:
Immunohistochemical Reactivity of the 14 F7 Monoclonal Antibody
Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant
Skin Neoplasms. ISRN Dermatol 2011, 2011:848909.
20. Hamamura K, Furukawa K, Hayashi T, Hattori T, Nakano J, Nakashima H,
Okuda T, Mizutani H, Hattori H, Ueda M, Urano T, Lloyd KO, Furukawa K:
Ganglioside GD3 promotes cell growth and invasion through p130Cas
and paxillin in malignant melanoma cells. Proc Natl Acad Sci U S A 2005,
102:11041–11046.
21. Miyata M, Kambe M, Tajima O, Moriya S, Sawaki H, Hotta H, Kondo Y,
Narimatsu H, Miyagi T, Furukawa K, Furukawa K: Membrane sialidase NEU3
is highly expressed in human melanoma cells promoting cell growthwith minimal changes in the composition of gangliosides. Cancer Sci
2011, 102:2139–2149.
22. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti
R, Anichini A, Mortarini R: NFATc2 is a potential therapeutic target in
human melanoma. J Invest Dermatol 2012, 132:2652–2660.
23. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni
N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A:
Role of Apollon in human melanoma resistance to antitumor agents that
activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res
2012, 18:3316–3327.
24. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre
GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G,
Parmiani G, Pierotti MA, Rodolfo M: BRAF alterations are associated with
complex mutational profiles in malignant melanoma. Oncogene 2004,
23:5968–5977.
25. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X,
Ferrone S: Association of antigen-processing machinery and HLA antigen
phenotype of melanoma cells with survival in American Joint Committee on
Cancer stage III and IV melanoma patients. Cancer Res 2006, 66:6405–6411.
26. Anichini A, Mazzocchi A, Fossati G, Parmiani G: Cytotoxic T lymphocyte
clones from peripheral blood and from tumor site detect intratumor
heterogeneity of melanoma cells. Analysis of specificity and mechanisms
of interaction. J Immunol 1989, 142:3692–3701.
27. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka
D, Mortarini R, Parmiani G, Fais S, Anichini A: Mutually exclusive NRASQ61R
and BRAFV600E mutations at the single-cell level in the same human
melanoma. Oncogene 2006, 25:3357–3364.
28. Tringali C, Lupo B, Cirillo F, Papini N, Anastasia L, Lamorte G, Colombi P,
Bresciani R, Monti E, Tettamanti G, Venerando B: Silencing of membrane-
associated sialidase Neu3 diminishes apoptosis resistance and triggers
megakaryocytic differentiation of chronic myeloid leukemic cells K562
through the increase of ganglioside GM3. Cell Death Differ 2009, 16:164–174.
29. Scaringi R, Piccoli M, Papini N, Cirillo F, Conforti E, Bergante S, Tringali C,
Garatti A, Gelfi C, Venerando B, Menicanti L, Tettamanti G, Anastasia L: NEU3
sialidase is activated under hypoxia and protects skeletal muscle cells
from apoptosis through the activation of the epidermal growth factor
receptor signaling pathway and the hypoxia-inducible factor (HIF)-
1alpha. J Biol Chem 2013, 288:3153–3162.
30. Scandroglio F, Loberto N, Valsecchi M, Chigorno V, Prinetti A, Sonnino S:
Thin layer chromatography of gangliosides. Glycoconj J 2009, 26:961–973.
31. Casadesus AV, Fernandez-Marrero Y, Clavell M, Gomez JA, Hernandez T,
Moreno E, Lopez-Requena A: A shift from N-glycolyl- to N-acetyl-sialic
acid in the GM3 ganglioside impairs tumor development in mouse
lymphocytic leukemia cells. Glycoconj J 2013, 30:687–699.
32. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, Rengifo E,
Perez R, Fernandez LE: A mouse IgG1 monoclonal antibody specific for
N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.
Hybridoma 2000, 19:241–247.
33. Mortarini R, Gismondi A, Maggioni A, Santoni A, Herlyn M, Anichini A:
Mitogenic activity of laminin on human melanoma and melanocytes:
different signal requirements and role of beta 1 integrins. Cancer Res
1995, 55:4702–4710.
34. Tringali C, Cirillo F, Lamorte G, Papini N, Anastasia L, Lupo B, Silvestri I,
Tettamanti G, Venerando B: NEU4L sialidase overexpression promotes
beta-catenin signaling in neuroblastoma cells, enhancing stem-like
malignant cell growth. Int J Cancer 2012, 131:1768–1778.
35. Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G, Venerando
B: The plasma membrane sialidase NEU3 regulates the malignancy of
renal carcinoma cells by controlling beta1 integrin internalization and
recycling. J Biol Chem 2012, 287:42835–42845.
36. Tringali C, Anastasia L, Papini N, Bianchi A, Ronzoni L, Cappellini MD, Monti
E, Tettamanti G, Venerando B: Modification of sialidase levels and
sialoglycoconjugate pattern during erythroid and erytroleukemic cell
differentiation. Glycoconj J 2007, 24:67–79.
37. Papini N, Anastasia L, Tringali C, Croci G, Bresciani R, Yamaguchi K, Miyagi T,
Preti A, Prinetti A, Prioni S, Sonnino S, Tettamanti G, Venerando B, Monti E:
The plasma membrane-associated sialidase MmNEU3 modifies the
ganglioside pattern of adjacent cells supporting its involvement in
cell-to-cell interactions. J Biol Chem 2004, 279:16989–16995.
38. Malykh YN, Schauer R, Shaw L: N-Glycolylneuraminic acid in human
tumours. Biochimie 2001, 83:623–634.
Tringali et al. BMC Cancer 2014, 14:560 Page 14 of 14
http://www.biomedcentral.com/1471-2407/14/56039. Varki A: N-glycolylneuraminic acid deficiency in humans. Biochimie 2001,
83:615–622.
40. Irie A, Suzuki A: CMP-N-Acetylneuraminic acid hydroxylase is exclusively
inactive in humans. Biochem Biophys Res Commun 1998, 248:330–333.
41. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD,
Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, Varki N, Varki A:
N-glycolylneuraminic acid deficiency in mice: implications for human
biology and evolution. Mol Cell Biol 2007, 27:4340–4346.
42. Yamaguchi K, Koseki K, Shiozaki M, Shimada Y, Wada T, Miyagi T: Regulation
of plasma-membrane-associated sialidase NEU3 gene by Sp1/Sp3
transcription factors. Biochem J 2010, 430:107–117.
43. Furukawa K, Horie M, Okutomi K, Sugano S, Furukawa K: Isolation and
functional analysis of the melanoma specific promoter region of human
GD3 synthase gene. Biochim Biophys Acta 2003, 1627:71–78.
44. Seyfried TN, Yu RK: Ganglioside GD3: structure, cellular distribution, and
possible function. Mol Cell Biochem 1985, 68:3–10.
45. Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, Ohmi Y,
Yamauchi Y, Furukawa K, Furukawa K: Ganglioside GD3 enhances
adhesion signals and augments malignant properties of melanoma cells
by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem
2010, 285:27213–27223.
46. Cheresh DA, Reisfeld RA, Varki AP: O-acetylation of disialoganglioside GD3
by human melanoma cells creates a unique antigenic determinant.
Science 1984, 225:844–846.
47. Schauer R: Sialic acids as regulators of molecular and cellular
interactions. Curr Opin Struct Biol 2009, 19:507–514.
48. Nystedt J, Anderson H, Hirvonen T, Impola U, Jaatinen T, Heiskanen A,
Blomqvist M, Satomaa T, Natunen J, Saarinen J, Lehenkari P, Valmu L, Laine J:
Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell
marker linked to stem cell-specific mechanisms. Stem Cells 2010, 28:258–267.
49. Osorio M, Gracia E, Rodriguez E, Saurez G, Arango Mdel C, Noris E, Torriella
A, Joan A, Gomez E, Anasagasti L, González JL, Melgares Mde L, Torres I,
González J, Alonso D, Rengifo E, Carr A, Pérez R, Fernández LE: Heterophilic
NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients:
results of a Phase Ib/IIa study. Cancer Biol Ther 2008, 7:488–495.
50. Gabri MR, Otero LL, Gomez DE, Alonso DF: Exogenous incorporation of
neugc-rich mucin augments n-glycolyl sialic acid content and promotes
malignant phenotype in mouse tumor cell lines. J Exp Clin Cancer Res
2009, 28:146.
51. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, Gasa S,
Watanabe A, Hasegawa T, Kuroki Y, Inokuchi J, Takahashi H: Detection of
N-glycolyated gangliosides in non-small-cell lung cancer using GMR8
monoclonal antibody. Cancer Sci 2013, 104:43–47.
52. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE: Role of
tumour-associated N-glycolylated variant of GM3 ganglioside in
cancer progression: effect over CD4 expression on T cells. Cancer
Immunol Immunother 2006, 55:443–450.
53. de Leon J, Fernandez A, Clavell M, Labrada M, Bebelagua Y, Mesa C,
Fernandez LE: Differential influence of the tumour-specific non-human
sialic acid containing GM3 ganglioside on CD4 + CD25- effector and
naturally occurring CD4 + CD25+ regulatory T cells function. Int Immunol
2008, 20:591–600.
54. Wang J, Yu RK: Interaction of ganglioside GD3 with an EGF receptor
sustains the self-renewal ability of mouse neural stem cells in vitro.
Proc Natl Acad Sci U S A 2013, 110:19137–19142.
55. Dong Y, Ikeda K, Hamamura K, Zhang Q, Kondo Y, Matsumoto Y, Ohmi Y,
Yamauchi Y, Furukawa K, Taguchi R, Furukawa K: GM1/GD1b/GA1 synthase
expression results in the reduced cancer phenotypes with modulation of
composition and raft-localization of gangliosides in a
melanoma cell line. Cancer Sci 2010, 101:2039–2047.
56. Bonaventure J, Domingues MJ, Larue L: Cellular and molecular
mechanisms controlling the migration of melanocytes and melanoma
cells. Pigment Cell Melanoma Res 2013, 26:316–325.
57. Kim SM, Jung JU, Ryu JS, Jin JW, Yang HJ, Ko K, You HK, Jung KY, Choo YK:
Effects of gangliosides on the differentiation of human mesenchymal
stem cells into osteoblasts by modulating epidermal growth factor
receptors. Biochem Biophys Res Commun 2008, 371:866–871.
58. Ravindranath MH, Tsuchida T, Morton DL, Irie RF: Ganglioside GM3:GD3
ratio as an index for the management of melanoma. Cancer 1991,
67:3029–3035.59. Kakugawa Y, Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I, Miyagi T:
Up-regulation of plasma membrane-associated ganglioside sialidase
(Neu3) in human colon cancer and its involvement in apoptosis
suppression. Proc Natl Acad Sci U S A 2002, 99:10718–10723.
60. Valaperta R, Chigorno V, Basso L, Prinetti A, Bresciani R, Preti A, Miyagi T,
Sonnino S: Plasma membrane production of ceramide from ganglioside
GM3 in human fibroblasts. FASEB J 2006, 20:1227–1229.
doi:10.1186/1471-2407-14-560
Cite this article as: Tringali et al.: Molecular subtyping of metastatic
melanoma based on cell ganglioside metabolism profiles. BMC Cancer
2014 14:560.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
